Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cheng-Ta Yang

Showing results (281-290 of 310) with videos related to

Pageof 31
Sort By:
Lung Cancer (Amsterdam, Netherlands)|February 2, 2025
First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trialKi Hyeong Lee, Jong-Seok Lee, Shunichi Sugawara, et al.
Future Oncology (London, England)|February 5, 2026
Plain language summary of TASUKI-52: A study looking at nivolumab plus platinum chemotherapy and bevacizumab as a combined treatment for people with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC)Shunichi Sugawara, Jong-Seok Lee, Jin-Hyoung Kang, et al.
Radiology|October 6, 2017
Accuracy of Presurgical Functional MR Imaging for Language Mapping of Brain Tumors: A Systematic Review and Meta-AnalysisHsu-Huei Weng, Kyle R Noll, Jason M Johnson, et al.
Cancer Science|January 29, 2026
Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52Jong-Seok Lee, Shunichi Sugawara, Jin-Hyoung Kang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 3, 2022
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON StudyMelissa L Johnson, Byoung Chul Cho, Alexander Luft, et al.
Frontiers in Oncology|July 26, 2021
Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb StudiesAntonio Passaro, Filippo de Marinis, Hai-Yan Tu, et al.
Chang Gung Medical Journal|November 7, 2012
Everolimus in metastatic renal cell carcinoma: preliminary experience from Chang Gung Memorial HospitalWen-Kuan Huang, Chuang-Chi Liaw, See-Tong Pang, et al.
Lung Cancer (Amsterdam, Netherlands)|November 22, 2023
Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON)Edward B Garon, Byoung Chul Cho, Alexander Luft, et al.
Clinical Lung Cancer|November 27, 2025
Savolitinib Plus Osimertinib in Epidermal Growth Factor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trialJames Chih-Hsin Yang, Yuh-Min Chen, Ullas Batra, et al.
Plos One|September 13, 2014
Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinomaJeng-Sen Tseng, Chih-Liang Wang, Ming-Shyan Huang, et al.
Pageof 31

Showing results (281-290 of 310) with videos related to

Sort By:
Pageof 31
Lung Cancer (Amsterdam, Netherlands)|February 2, 2025
First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trialKi Hyeong Lee, Jong-Seok Lee, Shunichi Sugawara, et al.
Future Oncology (London, England)|February 5, 2026
Plain language summary of TASUKI-52: A study looking at nivolumab plus platinum chemotherapy and bevacizumab as a combined treatment for people with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC)Shunichi Sugawara, Jong-Seok Lee, Jin-Hyoung Kang, et al.
Radiology|October 6, 2017
Accuracy of Presurgical Functional MR Imaging for Language Mapping of Brain Tumors: A Systematic Review and Meta-AnalysisHsu-Huei Weng, Kyle R Noll, Jason M Johnson, et al.
Cancer Science|January 29, 2026
Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52Jong-Seok Lee, Shunichi Sugawara, Jin-Hyoung Kang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 3, 2022
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON StudyMelissa L Johnson, Byoung Chul Cho, Alexander Luft, et al.
Frontiers in Oncology|July 26, 2021
Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb StudiesAntonio Passaro, Filippo de Marinis, Hai-Yan Tu, et al.
Chang Gung Medical Journal|November 7, 2012
Everolimus in metastatic renal cell carcinoma: preliminary experience from Chang Gung Memorial HospitalWen-Kuan Huang, Chuang-Chi Liaw, See-Tong Pang, et al.
Lung Cancer (Amsterdam, Netherlands)|November 22, 2023
Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON)Edward B Garon, Byoung Chul Cho, Alexander Luft, et al.
Clinical Lung Cancer|November 27, 2025
Savolitinib Plus Osimertinib in Epidermal Growth Factor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trialJames Chih-Hsin Yang, Yuh-Min Chen, Ullas Batra, et al.
Plos One|September 13, 2014
Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinomaJeng-Sen Tseng, Chih-Liang Wang, Ming-Shyan Huang, et al.
Pageof 31